Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TVGN Tevogen Bio Holdings

Not Yet Opened 03-19 16:00:00 EDT

5.31

-0.02

-0.38%

盘后5.24

-0.07-1.23%

18:16 EDT

High5.33	Low5.04	Vol23.12K
Open5.20	D1 Closing5.33	Amplitude5.44%
Mkt Cap21.40M	Tradable Cap2.69M	Total Shares4.03M
T/O121.82K	T/O Rate4.56%	Tradable Shares507.23K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":5.31,"timestamp":1773950400000,"preClose":5.33,"halted":0,"volume":23115,"hourTrading":{"tag":"盘后","latestPrice":5.2445,"preClose":5.31,"latestTime":"18:16 EDT","volume":815,"amount":4294.652,"timestamp":1773958586310,"change":-0.0655,"changeRate":-0.012335,"amplitude":0.012335},"delay":0,"changeRate":-0.0037523452157599366,"floatShares":507234,"shares":4030445,"eps":-9.40695,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"03-19 16:00:00 EDT","open":5.2,"high":5.33,"low":5.04,"amount":121821.26243249999,"amplitude":0.054409,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.40695,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773993600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":5.33,"postHourTrading":{"tag":"盘后","latestPrice":5.2445,"preClose":5.31,"latestTime":"18:16 EDT","volume":815,"amount":4294.652,"timestamp":1773958586310,"change":-0.0655,"changeRate":-0.012335,"amplitude":0.012335},"volumeRatio":0.362749},"requestUrl":"/m/hq/s/TVGN","defaultTab":"news","newsList":[{"id":"2619127891","title":"Tevogen Bio Holdings - Lead Investor Confirmed Intention to Maintain Current Shareholdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2619127891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619127891?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:45","pubTimestamp":1773427536,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4011C1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2619112781","title":"Tevogen Bio Holdings Inc - Board Continues to Evaluate Potential One-Time Special Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2619112781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619112781?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:45","pubTimestamp":1773427536,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4011C1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2619112787","title":"Tevogen Bio says it will use no more than 1% of authorized shares over the next 12 months","url":"https://stock-news.laohu8.com/highlight/detail?id=2619112787","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619112787?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:45","pubTimestamp":1773427518,"startTime":"0","endTime":"0","summary":"Tevogen said its lead investor, Manmohan Patel, intends to maintain his current shareholdings. The company said it does not anticipate using more than 1% of its authorized shares, including placements through its ATM, over the next 12 months or until it becomes cash-flow positive. Tevogen said about one-fifth of total shares outstanding are in the tradable float when accounting for holdings by the lead investor, directors and named executive officers. The board is evaluating a potential one-time special cash dividend contingent on future financial milestones. Tevogen said it is evaluating acquisitions that could generate more than USD 50 million in combined annual revenue, and cited independent valuations in 2022 that estimated the company at more than USD 4 billion before it went public.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDLmtSPz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","TVGN","BK4588","BK4139","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","SG9999014039.USD","LU2210150020.SGD","LU0314104364.USD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2619114727","title":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114727?lang=en_us&edition=fundamental","pubTime":"2026-03-14 01:54","pubTimestamp":1773424469,"startTime":"0","endTime":"0","summary":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen BioWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL6N4010OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VEON","ULTA","RJF","HBAN","AMAT","CMCT","CVNX","VACH","KLAR","LVWR","INDV","IMM.AU","IBG","CCUP","CVNA","CRCD","BW","BIAF","PODD","PAR","SDHC","ICRC","AIFF","ARES","FITB","WDCX","CRCA","KYIV","ADBG","DOUG","INMD","CVNY","CRCO","AMPY","KLC","TVGN","OFRM","SANA","SVCO","CRVS","ESQ","ISPC"],"gpt_icon":1},{"id":"2619111673","title":"BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push","url":"https://stock-news.laohu8.com/highlight/detail?id=2619111673","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619111673?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:43","pubTimestamp":1773420216,"startTime":"0","endTime":"0","summary":"BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push** Shares of biotech firm Tevogen Bio TVGN.O rise as much as 7.9% to $6.87 in afternoon trading ** Co says its Tevogen.AI platform improved accuracy in predicting drug targets most likely to work in patients, helping cut trial-and-error in drug development** Platform now analyzes more than 655 mln peptide sequences from about 24 mln proteins, drawing on data from 37 mln scientific papers, co says** TVGN adds its PredicTcell model lifted recall to 92% from 87% and precision to 48% from 40% in recent tests** Says it is seeking partnerships with drugmakers to advance select peptide candidates across cancer, virus and brain disease programs** Shares down ~68% in 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL4N4011F7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2619227111","title":"Tevogen reports performance advancements for Tevogen.AI platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2619227111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619227111?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:40","pubTimestamp":1773420031,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI. Over the past year, the co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-reports-performance-advancements-for-tevogen-ai-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-reports-performance-advancements-for-tevogen-ai-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2619113431","title":"Tevogen reports PredicTcell Beta recall at 92% and precision at 48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619113431","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619113431?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:30","pubTimestamp":1773419416,"startTime":"0","endTime":"0","summary":"Tevogen said beta testing of its PredicTcell model showed recall rising to 92% from 87%, a 5 percentage point increase. Precision increased to 48% from 40%, an 8 percentage point gain. Tevogen said the current version is trained on 1.8 million data points. The company said it has built a proprietary database of more than 655 million peptide sequences and analyzes 37 million scientific publications. Tevogen said Tevogen.AI operates three production AI agents that continuously evaluate 14 active peptide candidates.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL3yBK6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","NDAQ","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","BK4112","SG9999014013.SGD","LU0314104364.USD","BK4139","LU2210149790.SGD","TVGN","BK4588","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2619113151","title":"Tevogen.AI Reports Advancements in Predictcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2619113151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619113151?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:30","pubTimestamp":1773419400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nTUA6BCVCG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2618978368","title":"Tevogen Bio Holdings Inc - Evaluating Acquisition of Sciometrix and Clinicus Platform for Long Covid Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2618978368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618978368?lang=en_us&edition=fundamental","pubTime":"2026-03-12 03:15","pubTimestamp":1773256542,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ11G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2618978365","title":"Tevogen accelerates TVGN 489 Long COVID program as HLA coverage reaches 65% of U.S. population","url":"https://stock-news.laohu8.com/highlight/detail?id=2618978365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618978365?lang=en_us&edition=fundamental","pubTime":"2026-03-12 03:15","pubTimestamp":1773256525,"startTime":"0","endTime":"0","summary":"Tevogen said it is accelerating its Biotech and Digital Health verticals to move investigational TVGN 489 into its next clinical phase. Tevogen cited proof-of-concept data showing 100% of treated high-risk patients did not develop Long COVID. The company said identifying five additional HLA targets expanded potential eligibility for TVGN 489 to about 65% of the U.S. population. Tevogen also said it is evaluating the acquisition of Sciometrix and its Clinicus platform for real-world monitoring and data collection in future trials.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL2CYkwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","SG9999014021.USD","BK4139","IE00BKPKM429.USD","BK4112","LU0314104364.USD","SG9999014013.SGD","SG9999014005.SGD","LU2210150020.SGD","LU2095319765.USD","SG9999014039.USD","TVGN"],"gpt_icon":0},{"id":"2618360625","title":"Tevogen appoints interim leaders across core business verticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2618360625","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618360625?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:51","pubTimestamp":1773057082,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-appoints-interim-leaders-across-core-business-verticals-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-appoints-interim-leaders-across-core-business-verticals-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2618623154","title":"Tevogen names interim leaders for digital health, generics, contract research, biotech and AI verticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623154","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623154?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:45","pubTimestamp":1773056720,"startTime":"0","endTime":"0","summary":"Tevogen named interim leaders across five business verticals as part of its diversified growth strategy. Digital Health will be led by Arpita Patel and Wojtek Stobinski, while Generics will be led by Sadiq Khan and David Banko. William Keane was designated to lead Contract Research, Lori Grosso to lead Biotech, and Mittul Mehta to lead Artificial Intelligence. The company said it is evaluating strategic opportunities expected to operate as subsidiaries and collectively generate more than 50 million in annual revenue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLbJw4CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","BK4112","NDAQ","SG9999014013.SGD","LU2210149790.SGD","SG9999014039.USD","TVGN","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","BK4139","SG9999014021.USD"],"gpt_icon":0},{"id":"2618125623","title":"Press Release: Tevogen Names Leadership Team to Execute Diversified Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618125623","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618125623?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:45","pubTimestamp":1773056700,"startTime":"0","endTime":"0","summary":"WARREN, N.J., March 09, 2026  -- Tevogen   today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy.In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements.-- Digital Health: Arpita Patel and Wojtek Stobinski. Tevogen Bio, the company's lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio's pipeline spans virology, oncology, and neurology, with programs built on the company's proprietary ExacTcell platform.This press release contains certain forward-looking statements, including wit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","03160","TM","BK4604","BK4120","BK4139","TISI","BK4099","BK4588","BK4585","TVGN"],"gpt_icon":0},{"id":"2617302256","title":"Tevogen CEO says ‘actively evaluating potential acquisitions’","url":"https://stock-news.laohu8.com/highlight/detail?id=2617302256","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617302256?lang=en_us&edition=fundamental","pubTime":"2026-03-07 04:45","pubTimestamp":1772829938,"startTime":"0","endTime":"0","summary":"Dr. Ryan Saadi, Founder & CEO Tevogen (TVGN), sent the following letter to shareholders: “Dear Shareholders, As we continue executing on Tevogen’s ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-ceo-says-actively-evaluating-potential-acquisitions-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-ceo-says-actively-evaluating-potential-acquisitions-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2617632300","title":"Tevogen Bio Explores Buyout To Boost Generics Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2617632300","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617632300?lang=en_us&edition=fundamental","pubTime":"2026-03-07 01:42","pubTimestamp":1772818920,"startTime":"0","endTime":"0","summary":"Tevogen stock swings after Apozeal acquisition talks and a 50-for-1 reverse split as TVGN trades near lows.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/06/MA.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/06/MA.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/m-a/26/03/51104662/tevogen-bio-explores-buyout-to-boost-generics-platform","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/m-a/26/03/51104662/tevogen-bio-explores-buyout-to-boost-generics-platform","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4217","SMA","BK4139","TVGN"],"gpt_icon":0},{"id":"2617639862","title":"NASDAQ TRADE HALT CONTINUES  VOLATILITY TRADING PAUSE AT 10:14 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2617639862","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617639862?lang=en_us&edition=fundamental","pubTime":"2026-03-06 23:14","pubTimestamp":1772810062,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  VOLATILITY TRADING PAUSE AT 10:14 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nAQN2LP6KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2617038145","title":"Tevogen Bio Holdings Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2617038145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617038145?lang=en_us&edition=fundamental","pubTime":"2026-03-06 08:51","pubTimestamp":1772758272,"startTime":"0","endTime":"0","summary":"19:50 EST Tevogen (TVGN) Bio Holdings Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-bio-holdings-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-bio-holdings-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2617508450","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:50 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2617508450","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617508450?lang=en_us&edition=fundamental","pubTime":"2026-03-06 08:50","pubTimestamp":1772758200,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:50 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nAQN2LP04G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2617736865","title":"Tevogen signs LOI to evaluate potential acquisition of Apozeal Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2617736865","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617736865?lang=en_us&edition=fundamental","pubTime":"2026-03-06 04:00","pubTimestamp":1772740817,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with Ap...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-signs-loi-to-evaluate-potential-acquisition-of-apozeal-pharmaceutical-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-signs-loi-to-evaluate-potential-acquisition-of-apozeal-pharmaceutical-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2617573809","title":"Tevogen Bio Signs LOI to Evaluate Apozeal Pharmaceutical Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2617573809","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617573809?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:50","pubTimestamp":1772740214,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of Apozeal Pharmaceutical Inc., aiming to expand its Tevogen Generics strategy. Tevogen said Apozeal would bring an established generics platform, including 11 FDA-approved ANDA products for the U.S. market, additional ANDAs awaiting approval, and other generic products in development, subject to due diligence and definitive agreements.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1JjzSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014005.SGD","LU2210150020.SGD","SG9999014013.SGD","LU0314104364.USD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014039.USD","TVGN","BK4139","IE00BKPKM429.USD","BK4112","SG9999014021.USD","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://semperparatusspac.com","stockEarnings":[{"period":"1week","weight":-0.1677},{"period":"1month","weight":-0.6154},{"period":"3month","weight":-0.7203},{"period":"6month","weight":-0.86},{"period":"1year","weight":-0.9068},{"period":"ytd","weight":-0.6793}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.040664},{"month":2,"riseRate":0.6,"avgChangeRate":0.049009},{"month":3,"riseRate":0.4,"avgChangeRate":-0.252474},{"month":4,"riseRate":0.5,"avgChangeRate":-0.189171},{"month":5,"riseRate":0.25,"avgChangeRate":0.008552},{"month":6,"riseRate":0.25,"avgChangeRate":-0.034979},{"month":7,"riseRate":0.5,"avgChangeRate":-0.078575},{"month":8,"riseRate":0.5,"avgChangeRate":-0.064152},{"month":9,"riseRate":0.5,"avgChangeRate":-0.105281},{"month":10,"riseRate":0.75,"avgChangeRate":1.418967},{"month":11,"riseRate":0.5,"avgChangeRate":-0.189646},{"month":12,"riseRate":0.5,"avgChangeRate":-0.111833}],"exchange":"NASDAQ","name":"Tevogen Bio Holdings","nameEN":"Tevogen Bio Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tevogen Bio Holdings,TVGN,Tevogen Bio Holdings股票,Tevogen Bio Holdings股票老虎,Tevogen Bio Holdings股票老虎国际,Tevogen Bio Holdings行情,Tevogen Bio Holdings股票行情,Tevogen Bio Holdings股价,Tevogen Bio Holdings股市,Tevogen Bio Holdings股票价格,Tevogen Bio Holdings股票交易,Tevogen Bio Holdings股票购买,Tevogen Bio Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}